A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

NCT07024407 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterotopic Ossification (HO)

Interventions

DRUG: Andecaliximab

Sponsor

Ashibio Inc